Aktienanalyse zu Perrigo Company PLC (PRGO)PRGOPerrigo Company PLC

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Perrigo Company PLC is a good buy right now due to its current price of $15.06 being below the analyst target price of $15.25, suggesting room for growth. Additionally, the stock has shown a 5-day change of +5.61%, indicating positive momentum. However, investors should be cautious of the company's recent financial challenges, including a net income loss of $398.6 million in Q1 2026, which poses a risk to profitability.

18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.